Zandoriah
Teriparatide biosimilar developed by CinnaGen. Reference product Forsteo (Forteo in the United States).
Brands by market: Zandoriah (EU) · Commercial partner or holder: CinnaGen · Company profile
FDANot listed
EMAApr 2026authorised
MHRANot listed
PMDANot listed
HCNot listed
CDSCONot listed
EDENot listed
Approved or registered in 1 of 7 markets
Connections
About Zandoriah
Zandoriah is CinnaGen's teriparatide, approved in Europe in April 2026 after an earlier application was withdrawn and refiled. CinnaGen is Iran's largest biotechnology company, and this is its first European approval.
Status by market
FDA
United States
Not listed by FDA.
EMA
European Union · Zandoriah
European Medicines Agency and European CommissionApprovedBrand
Zandoriah
Holder or applicant
CinnaGen Co Unipessoal LDA
Pathway
Centralised (Article 10(4))
Approved
Apr 2026
Application or permission
EMEA/H/C/006688
Presentations
see SmPC
Remarks
An earlier application, Teriparatide Cinnagen, was withdrawn.
Source
S017 (EMA) · checked Sep 2026
MHRA
United Kingdom
Not listed by MHRA.
PMDA
Japan
Not listed by PMDA.
HC
Canada
Not listed by HC.
CDSCO
India
Not listed by CDSCO.
EDE
United Arab Emirates
Not listed by EDE.
Other developers in the same markets
Where Zandoriah holds an approval, these are the other teriparatide biosimilars approved in that market.
| Market | Rivals | Developers (product) |
|---|---|---|
| EMA | 4 | Gedeon Richter (Terrosa / Movymia), Intas Pharmaceuticals (Sondelbay / Intas teriparatide), Not stated in the EMA table (Livogiva), Strides Pharma (Kauliv) |
Chronology
- EMAApr 2026Authorised by the European Commission
Sources
S017EMA, medicines data table (medicines-output-medicines-report_en.xlsx) Primary (regulator)
Planning teriparatide biosimilar development?
EvySaif can help assess your regulatory pathway, clinical evidence requirements and market-entry strategy across India, UAE and other target markets.
Talk to a biosimilar regulatory consultantData current to September 2026.